CD3/CD20 Bispecific Antibody Step-Up Dosing for B-NHL
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bispecific antibodies targeting CD3 and CD20 face challenges such as low efficacy, severe adverse effects, and immunogenicity, limiting their effectiveness in treating cancers like B-NHL.
Innovation Solution
Development of a bispecific antibody, epcoritamab, with specific dose ranges and dosage regimens for targeting CD3 and CD20, optimized for treating B-cell lymphomas, including DLBCL and FL, to enhance therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bispecific antibodies targeting CD3 and CD20 are used to treat cancer, then T cell recruitment to antigen-expressing cancer cells is improved, but severe adverse effects (cytokine storm) occur
Solution Approach 1:
The patent applies preliminary action by implementing a step-up dosing regimen where the bispecific antibody is administered at increasing doses over multiple administrations. This gradual escalation allows the immune system to adapt progressively, preventing the sudden overwhelming activation that causes cytokine storm while still achieving effective T cell recruitment to cancer cells over time.
Solution Approach 2:
The patent applies dynamics by using a flexible, adaptive dosing schedule that adjusts the amount and frequency of antibody administration based on patient response and tolerance. This dynamic approach allows optimization of therapeutic efficacy while minimizing adverse effects, as the dosing can be tailored to each patient's immune system characteristics and disease state.
2Reliability
If bisspecific antibodies targeting CD3 and CD20 are used to treat cancer, then T cell recruitment to antigen-expressing cancer cells is improved, but immunogenicity increases
Solution Approach 1:
The patent applies parameter changes by modifying the dosing parameters (dose amount, frequency, and duration) of the bispecific antibody administration. By optimizing these parameters, the treatment achieves sufficient therapeutic efficacy while minimizing the immune system's recognition and rejection of the antibody, thereby reducing immunogenicity-related adverse effects.
3Productivity
If high doses of bispecific antibody are administered to improve efficacy, then therapeutic effectiveness increases, but adverse effects worsen
Solution Approach 1:
The patent applies preliminary action by administering the bisspecific antibody at low initial doses before escalating to higher therapeutic doses. This preliminary low-dose exposure primes the system and allows gradual adaptation, enabling subsequent high-dose administrations to achieve therapeutic effectiveness with reduced adverse effects compared to immediate high-dose treatment.
Solution Approach 2:
The patent applies periodic action through a dosing regimen that spaces out antibody administrations over time intervals. This periodic administration allows the body to process and respond to each dose before the next is given, maintaining therapeutic effectiveness while preventing the accumulation of adverse effects that would occur with continuous high-dose treatment.
Data Source
AI summary
The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).